Lupin Ltd - New Drugs Approvals Will Boost Future Prospects
The combined sales from these three drugs could potentially generate incremental sales of ~$100 Mn per year in the US market.
209 Views
Lupin Ltd - GSpiriva on a Healthy Growth Track, Headwinds Receding
This to result in $200-220 million sales on a quarterly basis. USFDA recently completed cGMP inspection of Dabhasa plant and zconcluded with no...
167 Views
LUPIN Ltd - Margins Guidance Increased
The company’s sales increased by 20.2% YoY to Rs 5,197 Cr, and the growth was majorly led by its US business of $212 (+0.5% Q0Q).
413 Views
Indegene Pre-IPO - RHP Updates - Client Base Continued to Grow, and Margins Have Begun Stabilizing
Indegene Limited (1864095D IN) is looking to raise about US$220m in its upcoming India IPO. We looked at the firm’s past performance in an earlier...
121 Views
LUPIN Ltd - Positive Outlook Backed by the Launch of Niche Products
The company’s sales were up 28.6% YoY at Rs 4,330 Cr, and the growth was majorily led by its India business (+9.8% YoY), EMEA (+19.6% YoY)
265 Views